Live Feeds
● TRACKER Updated 19d ago · 8 sources tracked

Thyroid tablets recalled nationwide over potential ‘superpotency’: FDA

The FDA has announced a nationwide recall of thyroid tablets due to potential 'superpotency', which can lead to hyperthyroidism. The affected product is Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg, specifically lot number 504950. The recall was issued as a precautionary measure to prevent adverse effects, particularly in elderly and pregnant patients.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The recall affects Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg.
  • ✓ The specific lot number affected is 504950.
  • ✓ The tablets may be 'superpotent', leading to hyperthyroidism.
  • ✓ The recall was issued as a precautionary measure to prevent adverse effects.
🛡️ Source Corroboration: 8 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

The FDA's announcement of the recall provides further details on the affected product and the reasons for the recall.

Live updates

  1. Thyroid tablets recalled nationwide over potential 'superpotency'

    The FDA has announced a nationwide recall of thyroid tablets due to potential 'superpotency', which can lead to hyperthyroidism. The affected product is Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg, specifically lot number 504950. The recall was issued as a precautionary measure to prevent adverse effects, particularly in elderly and pregnant patients.

    Why it matters

    The recall was issued due to concerns that the tablets may be 'superpotent', meaning they contain more active ingredients than stated, which can cause hyperthyroidism. Hyperthyroidism can lead to symptoms such as weight loss, rapid heartbeat, and anxiety. The recall affects patients who rely on thyroid medication to regulate their hormone levels.

    What is confirmed

    • The recall affects Vitruvias Therapeutics' Thyroid Tablets, USP 30 mg.
    • The specific lot number affected is 504950.
    • The tablets may be 'superpotent', leading to hyperthyroidism.
    • The recall was issued as a precautionary measure to prevent adverse effects.
    • Elderly and pregnant patients are particularly at risk.

    What to watch next

    • Further updates on the recall and any additional lots affected
    • Reports of adverse effects from patients taking the affected tablets
    • The FDA's ongoing investigation into the cause of the 'superpotency' issue
    Sources used for this update (8)
    1. NBC 5 Chicago — Thyroid tablets recalled because they could be ‘superpotent,' lead to hyperthyroidism
    2. USA Today — Thyroid medicine recalled. See affected product
    3. FOX 8 News — Thyroid tablets could be ‘superpotent,’ warns FDA in urgent recall alert
    4. WTHR — Thyroid medication recalled as product can be 'superpotent,' FDA says
    5. The Hill — Thyroid tablets recalled nationwide over potential ‘superpotency’: FDA
    6. www.ibtimes.co.uk — Vitruvias Therapeutics Thyroid Tablet Recall: 'Superpotent' Pills Risk Elderly and Pregnant Patients
    7. www.yahoo.com — FDA Announces Recall of Thyroid Medicine Due to Potential “Super Potency”
    8. www.fox9.com — Thyroid tablets recalled because they may be ‘superpotent’
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community